A New Era in Parkinson's Treatment: How Medications and Deep Brain Stimulation Are Reshaping Lives

Introduction

Parkinson's disease, a neurodegenerative disorder affecting over 10 million people worldwide, was once considered an "incurable disease." However, over the past decade, the treatment landscape has quietly transformed: Levodopa remains the gold standard but is no longer the only answer; deep brain stimulation (DBS) has shifted from a "last resort" to a "mid-stage option"; and targeted drugs and gene therapies are entering clinical practice. For Chinese patients, the good news is that these new therapies are not out of reach. This article outlines the latest advancements from medications to DBS and guides you on how to evaluate the right path for yourself.

Pharmacological Treatment: Beyond Levodopa

Novel Combination Formulations and Continuous Delivery

In 2024, the FDA approved ND0612 (subcutaneous continuous infusion of levodopa/carbidopa), which stabilizes blood drug concentrations and reduces "wearing-off" phenomena and dyskinesias. Clinical trials showed an average reduction of 2.3 hours in daily "off" time for motor symptoms. Additionally, inhaled levodopa (Inbrija) provides relief for "off" episodes, with onset of action in as little as 10 minutes. These advancements mean that early-stage patients can opt for more refined management strategies rather than proceeding directly to surgery.

Targeted New Drugs: GLP-1 Receptor Agonists

In a phase 2 trial published in the New England Journal of Medicine in 2024, lixisenatide (a GLP-1 class drug) slowed the progression of motor symptoms in early Parkinson's patients by approximately 30%. Although phase 3 validation is still needed, it offers new hope for neuroprotective therapy. The U.S. movement disorders centers partnered with MeiJiaKang have opened enrollment for related clinical trials, suitable for consideration by early-stage patients.

Deep Brain Stimulation: Precision Neuromodulation

Expanded Indications

Previously, DBS was reserved for patients with disease duration over 5 years and medication-refractory tremors. However, updated international guidelines in 2023 recommend evaluation as soon as medication-related motor complications (such as dyskinesias or fluctuations) appear, without waiting for years. Particularly for patients with tremor-dominant symptoms and good responses to levodopa, DBS efficacy rates can reach 70-85%.

Surgical Procedure and Risks

The DBS procedure involves three steps: preoperative MRI targeting, microelectrode recording to confirm the target, and implantation of electrodes connected to a chest-wall pulse generator. The patient remains awake and cooperative throughout, with the procedure lasting approximately 4-6 hours. One month post-surgery, the device is activated and parameters are adjusted, with most patients experiencing a reduction in "off" symptoms by over 50%. Risks include intracranial hemorrhage (<1%) and infection (2-5%), but these are manageable when performed by experienced stereotactic teams. Top U.S. centers, such as the Cleveland Clinic, perform over 500 DBS surgeries annually with complication rates below 2%.

International Medical Options: Why Seek DBS Treatment in the U.S.?

Technological Gap and Customized Solutions

DBS has been performed in China for over 20 years, but some centers still rely on traditional frame-based targeting. In the U.S., MRI-guided targeting, intraoperative electrophysiological monitoring, and closed-loop DBS (adaptive stimulation) are standard practice. Closed-loop DBS adjusts stimulation intensity in real time based on brain signals, reducing side effects and improving long-term efficacy. The Boston Scientific Vercise™ system, approved in 2024, features directional electrodes that can precisely avoid the internal capsule, reducing speech difficulties.

Objective Data Comparison

Patient satisfaction one year after DBS in the U.S. reaches 85%, compared to around 70% at some Chinese centers (depending on surgical volume). More importantly, U.S. hospitals provide preoperative multidisciplinary evaluations (movement disorder specialists, neuropsychologists, psychiatrists) to ensure patients are psychologically suitable for surgery. MeiJiaKang has assisted over 200 patients in traveling to the U.S. for DBS, reducing average wait times from 6-12 months domestically to 3-4 weeks, with transparent costs covering preoperative evaluation, surgery, and one year of postoperative follow-up.

Non-Surgical Frontiers: Focused Ultrasound and Gene Therapy

MRI-Guided Focused Ultrasound

Without requiring craniotomy, ultrasound is used to precisely ablate the ventral intermediate nucleus of the thalamus, achieving up to 90% efficacy for medication-refractory tremors, but it is limited to unilateral treatment. It is suitable for elderly patients or those unable to tolerate surgery. Currently covered by U.S. Medicare, it remains self-funded in China, costing approximately 150,000-200,000 RMB.

Gene Therapy Prospects

In a phase 2 trial in early 2025, AAV2-GDNF gene therapy showed significant improvements in motor function with no serious adverse events. Although market availability is still 3-5 years away, it offers long-term hope for younger patients.

Recommendations for International Patients

Evaluate Early: If motor complications arise, do not wait until they become "severe" to undergo DBS evaluation. Early intervention can better preserve quality of life.

Seek a Second Opinion: International multidisciplinary evaluation can rule out other conditions resembling Parkinson's (e.g., multiple system atrophy), avoiding misdiagnosis. MeiJiaKang can arrange remote video consultations with U.S. movement disorder specialists.

Compare Treatment Pathways: Use our cost estimator tool to understand cost differences between China and the U.S. for therapies like DBS and focused ultrasound.

Postoperative Rehabilitation: DBS is not the endpoint; ongoing physical therapy and speech training are crucial. MeiJiaKang collaborates with local rehabilitation centers in Shanghai to provide postoperative follow-up guidance.

Parkinson's is no longer a "terminal illness." From medications to DBS and gene therapy, new options exist at every stage. The key is finding the path that suits you best. MeiJiaKang will accompany you throughout, from evaluation to treatment, and through rehabilitation coordination after returning home. For assistance, please contact us to access one-on-one medical advisor support.